The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Time-evolution of in vivo protein corona onto blood-circulating PEGylated liposomal doxorubicin (DOXIL) nanoparticles
Open accessAbstract
Nanoparticles (NPs) are instantly modified once injected in the bloodstream because of their interaction with the blood components. The spontaneous coating of NPs by proteins, once in contact with biological fluids, has been termed the 'protein corona' and it is considered to be a determinant factor for the pharmacological, toxicological and therapeutic profile of NPs. Protein exposure time is thought to greatly influence the composition of protein corona, however the dynamics of protein interactions under realistic, in vivo conditions remain unexplored. The aim of this study was to quantitatively and qualitatively investigate the time evolution of in vivo protein corona, formed onto blood circulating, clinically used, PEGylated liposomal doxorubicin. Protein adsorption profiles were determined 10 min, 1 h and 3 h post-injection of liposomes into CD-1 mice. The results demonstrated that a complex protein corona was formed as early as 10 min post-injection. Even though the total amount of protein adsorbed did not significantly change over time, the fluctuation of protein abundances observed indicated highly dynamic protein binding kinetics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Time Evolution of the Nanoparticle Protein Corona
Casals, E., Pfaller, T., Duschl, A., Oostingh, G. J., & Puntes, V. (2010) · ACS Nano · doi:10.1021/nn901372t · Cited by 1,211
Pozzi, D., Colapicchioni, V., Caracciolo, G., Piovesana, S., Capriotti, A. L., Palchetti, S., De Grossi, S., Riccioli, A., Amenitsch, H., & Laganà, A. (2014) · Nanoscale · doi:10.1039/c3nr05559k · Cited by 581
Chanan-Khan, A., Szebeni, J., Savay, S., Liebes, L., Rafique, N. M., Alving, C. R., & Muggia, F. M. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg374 · Cited by 479
Hadjidemetriou, M., Al-Ahmady, Z., Mazza, M., Collins, R. F., Dawson, K., & Kostarelos, K. (2015) · ACS Nano · doi:10.1021/acsnano.5b03300 · Cited by 358
Self-citation
Cited by
DLS and zeta potential – What they are and what they are not?
Bhattacharjee, S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.017 · Cited by 4,702
PEG-PCL-based nanomedicines: A biodegradable drug delivery system and its application
Grossen, P., Witzigmann, D., Sieber, S., & Huwyler, J. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.05.028 · Cited by 496
Biological Identity of Nanoparticles In Vivo : Clinical Implications of the Protein Corona
Caracciolo, G., Farokhzad, O. C., & Mahmoudi, M. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2016.08.011 · Cited by 426
Rampado, R., Crotti, S., Caliceti, P., Pucciarelli, S., & Agostini, M. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00166 · Cited by 390
In vivo formation of protein corona on gold nanoparticles. The effect of their size and shape
García-Álvarez, R., Hadjidemetriou, M., Sánchez-Iglesias, A., Liz-Marzán, L. M., & Kostarelos, K. (2018) · Nanoscale · doi:10.1039/c7nr08322j · Cited by 373
Self-citation
Metadata
- Authors
- Hadjidemetriou, M., Al-Ahmady, Z., & Kostarelos, K.
- Venue
- Nanoscale
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2016
- Volume
- 8
- Issue
- 13
- Pages
- 6948-6957
- ISSN
- 2040-3364 (ISSN-L)
- 2040-3372
- OpenAlex
- W2288424886
- Cited by
- 214
- References
- 5
- FWCI
- 8.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Time-evolution of in vivo protein corona onto blood-circulating PEGylated liposomal doxorubicin (DOXIL) nanoparticles. https://app.cochat.ai/papers/10.1039/c5nr09158f
- The paper
- Hadjidemetriou, M., Al-Ahmady, Z., & Kostarelos, K. (2016). Time-evolution of in vivo protein corona onto blood-circulating PEGylated liposomal doxorubicin (DOXIL) nanoparticles. Nanoscale. https://doi.org/10.1039/c5nr09158f
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.